Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
We would like to thank Dr. Yu and his colleagues 1 for their interest in our recent transcriptome analysis from the IM-brave150 clinical trial, which resulted in the development of the ISS10 predictor. 2We are grateful for their thorough and insightful work in comparing 23 predictive gene expression signatures for immunotherapy and assessing the predictability of each using the clinical outcomes from the IMbrave150 trial. 3,4Their comprehensive analysis has added valuable depth to the ongoing discussion in finding and validating robust biomarkers and prediction models for immunotherapy in hepatocellular carcinoma (HCC).We are pleased to see
Authors
- Ji Hoon Kim (ORCID: https://orcid.org/0000-0003-3924-0434)
- Ahmed Omar Kaseb (ORCID: https://orcid.org/0000-0002-9491-0587)
- Sun Young Yim (ORCID: https://orcid.org/0000-0001-7346-5974)
- Sunyoung S. Lee (ORCID: https://orcid.org/0000-0002-5954-5991)
- Ju‐Seog Lee (ORCID: https://orcid.org/0000-0002-5666-9753)
- Sung-Hwan Lee (ORCID: https://orcid.org/0000-0003-0783-7033)
- Peng Wei (ORCID: https://orcid.org/0000-0002-8048-7909)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Korea University (KR)
- CHA University Bundang Medical Center (KR)
- CHA University (KR)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2024-10-02
- DOI
- https://doi.org/10.3350/cmh.2024.0828
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Duncan Family Institute for Cancer Prevention and Risk Assessment
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute